Friday, July 10, 2026

pharma · Anorectal Disorder · Localized Primary Osteoarthritis of Both Hips (Diagnosis)

Chia Tai Tianqing

Chia Tai Tianqing is a pharma organization headquartered in CN. Primary therapeutic focus areas include Anorectal Disorder, Localized Primary Osteoarthritis of Both Hips (Diagnosis), Recovery of Bowel Function, Due to Gu

Lianyungang, CN HQ
366 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Lianyungang, CN
Employees
366
Programs
11
Drugs
15
Patents
0
Clinical program

risperidone

Approved · small molecule · Neuroleptic-Induced Tardive Dyskinesia

risperidone for Neuroleptic-Induced Tardive Dyskinesia is a Approved program (small_molecule) at Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Internal code TMH-91-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Phase
Approved
Modality
small_molecule
Indication
Neuroleptic-Induced Tardive Dyskinesia
Status
completed
Trials
1